Investment report on Rexahn Pharmaceuticals

StockPreacher.com announces an investment report featuring Rexahn Pharmaceuticals Inc. (AMEX:RNN). The report includes financial, comparative and investment analyses, and industry information you need to know to make an educated investment decision.

The full report is available at: http://www.stockpreacher.com/n/RNN

Get our alerts BEFORE the rest of the market. Follow us on Twitter: https://twitter.com/StockPreacher

Rexahn Pharmaceuticals Inc. (RNN) is a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of treatments for cancer, central nervous system (CNS) disorders, sexual dysfunction and other medical needs. The Company develops therapies that make it possible to regain normalcy for patients suffering from disease. It has three drug candidates in phase II clinical trials during the year ended December 31, 2008, and six or more other drug candidates in pre-clinical development.

Message Board Search for RNN: http://www.boardcentral.com/boards/RNN

In the report, the analyst notes:

"For each of the three and nine month periods ended September 30, 2009, RNN recorded revenues of $18,750 and $56,250, respectively.  RNN recorded the same amounts in the periods of 2008.  In all periods, the revenue reflects the recognition of deferred revenue from a collaborative research agreement with Rexgene Biotech Co. Ltd., a minority stockholder. 

"RNN recently announced that it has submitted a phase II protocol to the U.S. Food and Drug Administration (FDA) for the clinical study of Serdaxin for the treatment of Parkinson's disease (PD). The phase II study will assess Serdaxin's efficacy as a treatment for Parkinson's disease in approximately 300 subjects.  The planned double blind, randomized, placebo-controlled trial will include the Unified Parkinson's Disease Rating Scale (UPDRS) and quality of life instruments as study endpoints and will be conducted at multiple sites. RNN also has formed a Parkinson's Scientific Advisory Board (SAB) composed of leading medical researchers in the field of neurology who will advise on the design and development of the Serdaxin clinical trials."